Context
*******
https://chatgpt.com/c/696dd048-75ec-832d-92eb-2a1356f33040

- Lower limb venous insufficiency
- For a scientific publication, we follow the evolution of VEINES QOL (and Sym) according to timepoints T0, T1, T2 where T0 = RFA surgery of lower limb.

The input is : 30 patients : df_fram :

   workbook                                                                 patient_id        timepoint  iter_t  
0               2025-11-01 2025-11-01 T0 PT_2024_02_00078 MAKOLA ODETTE V03  PT_2024_02_00078  T0        46.8    
1      2025-11-01 2025-11-01 T0 PT_2024_02_08277 KAVIRA ZAWADI CLAUDINE V03  PT_2024_02_08277  T0        47.2 
2         2025-11-01 2025-11-01 T0 PT_2024_02_10578 NSIALA KIMANGA BIBI V03  PT_2024_02_10578  T0        50.8
...

We have established QOL / Sym evolution based on :

(1)	their t-score :
-----------------
# Raw  : df_fram
# ===
df_fram = (df_fram.groupby("timepoint").agg(mean=("iter_t", "mean"),sd=("iter_t", "std"),n=("iter_t", "count")).reset_index())
df_fram["se"] = df_fram["sd"] / np.sqrt(df_fram["n"])
df_fram["ci_lower"] = df_fram["mean"] - 1.96 * df_fram["se"]
df_fram["ci_upper"] = df_fram["mean"] + 1.96 * df_fram["se"]
 
(2) modeling that t-score
-------------------------
# Model  : df_modl
# ===
import statsmodels.formula.api as smf
model = smf.mixedlm("iter_t ~ C(timepoint)", df_modl, groups=df_modl["patient_id"])

We produce :
- the evolution of the t-score (both 'raw' and 'modelled') on the timepoints
- the delta of those score with respect to T0

Possible Evolution
******************
In parallel to the QOL, we have the VCSS R, L limb data at those timepoints. 
The idea is to have 'medical aspect' data in complement to 'patient viewpoint' data 

Input :

   workbook                                                                 patient_id        timepoint   VCSS_R   VCSS_L 
0               2025-11-01 2025-11-01 T0 PT_2024_02_00078 MAKOLA ODETTE V03  PT_2024_02_00078  T0         5        5 
1      2025-11-01 2025-11-01 T0 PT_2024_02_08277 KAVIRA ZAWADI CLAUDINE V03  PT_2024_02_08277  T0         9        9  
...


We produce "median_iqr" :

| ID                   | Metric   | Timepoint   | Value          |
|:---------------------|:---------|:------------|:---------------|
| StatTranVCSS_01_desc | VCSS_R   | T0          | 5.0 [3.2–8.8]  |
| StatTranVCSS_01_desc | VCSS_L   | T0          | 5.0 [3.0–10.8] |
| StatTranVCSS_01_desc | VCSS_R   | T1          | 5.0 [3.2–8.8]  |
| StatTranVCSS_01_desc | VCSS_L   | T1          | 5.0 [3.0–10.8] |
| StatTranVCSS_01_desc | VCSS_R   | T2          | 5.0 [3.2–8.8]  |
| StatTranVCSS_01_desc | VCSS_L   | T2          | 5.0 [3.0–10.8] |

as well as delta :

| Timepoint | Mean VCSS ( SD) | Median (Range) | 95% CI of Mean | p-value (vs T0) |
| :--- | :---: | :---: | :---: | :---: |
| **T0 (Baseline)** |  |  | [7.9, 8.9] | — |
| **T1 (Post-Op)** |  |  | [2.8, 3.6] |  |
| **T2 (Follow-up)** |  |  | [1.6, 2.2] |  |


Questions : reporting the VCSS data at each time point
*********
1- For this VCSS limb total (up to 30 max), we also could produce evolution outcome based on raw data and modelled data
The modelled VCSS total (if appropriate) would have to take both limb patient groupig into account. 
2- Does this approach make sense : medical data complementing patient data
3- If so, are there any medical scientific standards of computing/reporting VCSS evolutions (as we do have for QOL)  

Thank you for you valuable opinion


# ****
#
# ****

Thank you for the very clear context — this is a solid and well-thought-out analytical framework already. I’ll answer your three questions in a **methodological / scientific reporting** perspective, aligned with standards typically expected in vascular medicine publications.

---

## 1️⃣ Can VCSS be analysed with raw and modelled evolution (like VEINES QOL)?

### **Yes — with some important nuances**

### A. Nature of VCSS (key point)

VCSS is:

* **Clinician-reported**
* **Ordinal / semi-quantitative**
* Bounded (0–30 per limb; total often 0–60 if summed)

This contrasts with VEINES QOL/Sym:

* **Patient-reported**
* Designed to be treated as **continuous**, often normalized (t-scores)

➡️ This affects **model choice**, not whether modelling is appropriate.

---

### B. Raw (descriptive) evolution — strongly recommended

Your current approach is **fully appropriate and standard**:

* Median [IQR]
* Mean ± SD
* Change vs T0
* Non-parametric tests (Wilcoxon / Friedman) often preferred

This is exactly how VCSS is most often reported in the literature.

---

### C. Modelled VCSS — acceptable and increasingly used

You **can** model VCSS evolution, but you should choose the structure carefully.

#### Option 1 — Limb-level model (recommended if limb-specific)

Long format:

```text
patient_id | timepoint | limb | vcss
```

Model examples:

**Linear mixed model (pragmatic, commonly accepted):**

```python
vcss ~ C(timepoint) + C(limb)
random intercept: patient_id
```

or with correlation:

```python
random intercepts: patient_id / limb
```

This:

* Accounts for **within-patient correlation**
* Keeps **R/L limb information**
* Is easy to interpret for clinicians

**Caveat**: Linear models assume approximate continuity. This is usually tolerated for VCSS in clinical journals.

---

#### Option 2 — Patient-level total VCSS

If you define:

```text
VCSS_total = VCSS_R + VCSS_L
```

Then:

```python
VCSS_total ~ C(timepoint) + (1 | patient_id)
```

✔️ Simpler
❌ Loses limb-specific clinical meaning
✔️ Often used in endovenous ablation studies

---

#### Option 3 — Ordinal or Poisson models (methodologically “pure”)

* Ordinal mixed models
* Poisson / negative binomial mixed models

✔️ Statistically rigorous
❌ Much harder to explain clinically
❌ Rarely required by reviewers unless journal is highly methodological

➡️ **Most vascular journals accept linear mixed models for VCSS**

---

### ✅ Recommendation

For a **clinical scientific paper**:

* **Primary**: raw median/IQR + change vs T0
* **Secondary (supportive)**: mixed-effects model (limb- or total-level)

---

## 2️⃣ Does “medical data complementing patient-reported data” make sense?

### **Absolutely — and reviewers will like it**

This is a **major strength** of your study.

You are combining:

* **Patient-reported outcomes** (VEINES QOL/Sym)
* **Clinician-reported severity** (VCSS)

This aligns perfectly with:

* Modern outcomes research
* Value-based healthcare
* ESVS / SVS recommendations

### Conceptually:

| Domain            | Instrument     | Perspective |
| ----------------- | -------------- | ----------- |
| Quality of life   | VEINES QOL/Sym | Patient     |
| Clinical severity | VCSS           | Physician   |

➡️ Showing **parallel improvement** strengthens causal interpretation of RFA benefit
➡️ Showing **discordance** (if any) is also scientifically valuable

---

## 3️⃣ Are there medical standards for computing/reporting VCSS evolution?

### **Yes — but less formalized than QOL scores**

### A. Common reporting standards in venous literature

Most studies report:

* Median (IQR) VCSS at each timepoint
* Mean change from baseline
* % improvement
* Statistical comparison vs baseline

Examples (typical phrasing):

> “Median VCSS decreased from 8 (IQR 6–11) at baseline to 3 (IQR 2–5) at 6 months (p < 0.001).”

Your tables already align with this.

---

### B. No official “t-score” or normalization for VCSS

Unlike VEINES:

* There is **no validated transformation**
* No population-based reference norms
* No minimal clinically important difference (MCID) universally accepted

Some papers mention:

* ≥4-point reduction as “clinically meaningful”
  But this is **not universally standardized**

---

### C. Increasing acceptance of longitudinal models

Recent high-quality papers:

* Use mixed models to describe trajectory
* Adjust for bilateral limbs
* Report estimated marginal means ± CI

Your approach would be considered **methodologically advanced but acceptable**.

---

## 📌 Suggested reporting strategy (practical)

### In Methods

* Describe VEINES and VCSS **separately**
* Explicitly state:

  * VCSS analysed per limb
  * Correlation handled via mixed-effects model
  * Raw descriptive statistics are primary

### In Results

1. **VEINES QOL/Sym**

   * Raw mean ± CI
   * Model-based estimates
   * Δ vs T0

2. **VCSS**

   * Median [IQR] per timepoint
   * Mean ± SD (optional)
   * Δ vs T0
   * Model-based trajectory (supportive)

### In Discussion

* Emphasize concordance between:

  * Patient-perceived improvement
  * Objective clinical severity reduction

---

## 🧠 Bottom line

✔️ Yes, VCSS can be analysed longitudinally (raw + modelled)
✔️ Yes, combining clinician and patient outcomes is scientifically strong
✔️ There is no rigid standard like VEINES t-scores, but your approach is **well within accepted medical practice**

If you want, I can:

* Propose **exact model formulas** (with justification wording)
* Help draft a **Methods subsection**
* Suggest **figures** that visually align QOL and VCSS trajectories

Just tell me 👍
